|Bid||1.5500 x N/A|
|Ask||1.5700 x N/A|
|Day's Range||1.3450 - 1.5700|
|52 Week Range||0.0900 - 1.9000|
|Beta (5Y Monthly)||2.02|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr. 20, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.88|
NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, is highlighting the latest CEO comments and news from companies recently presenting at its highly acclaimed NEXT SUPER STOCK livestream investor conferences, and investor “LiveChats” on social media streams. Over 170,000 investors have participated in Wall Street Reporter’s livestream events in the past 30 days. Tetra Bio-Pharma (OTC: TBPMF) (TSX: TBP) CEO, Dr. Guy Chamberland: “Expecting to Launch 3 New Cannabinoid-Derived Drugs in 2022 - Addressing $200 Billion Market Opportunities” In a recent presentation at Wall Street Reporter’s NEXT SUPER STOCK livestream, Tetra BioPharma (OTC: TBPMF) CEO, Dr. Guy Chamberland shared TBPMF’s advanced pipeline of cannabinoid derived drugs targeting $200 billion addressable market opportunities including pain, inflammation, oncology, and sepsis. TBPMF boasts one of the most advanced pipelines of Cannabinoid-derived medicines, supported by the urgent need for non-opioid alternatives to treat pain and inflammation. Significantly, TBPMF’s portfolio of IP and patents is spearheaded by a team experienced at bringing new drugs to market. TBPMF now has 3 drugs in the advanced clinical stages, which it expects to bring to market in 2022: Quixleef targeting pain management, a $58 billion market opportunity, ARDS-003 immunomodulator which is a $132 billion market opportunity, and PPP-003 for ophthalmic inflammation indication - a $31 billion market. Compelling for investors, TBMPF has multiple near-term catalysts in place, and with a current valuation of about $50 million, TBPMF is trading at a just a small fraction of it’s peer group in the biotech space, with similar pipelines. Watch Tetra Bio-Pharma (OTC: TBPMF) Next Super Stock 4/21/21 video: https://bit.ly/2QzBElc Red Light Holland (OTC: TRUFF) (CSE: TRIP) CEO Todd Shapiro: ”Psychedelics is Next Billion Dollar Market Opportunity” In a recent presentation on Wall Street Reporter’s NEXT SUPER STOCK livestream, Red Light Holland (OTC: TRUFF) (CSE: TRIP), CEO Todd Shapiro updated investors on the TRUFF’s latest market expansion and success in the psychedelics sector, and major new growth opportunities in coming months. TRUFF produces and sells recreational grade psychedelic Magic Truffles to the current legal adult use market in the Netherlands, and is planning global expansion as legislation is rapidly changing globally. TRUFF: “The Tesla of Psychedelics” Todd was joined by cannabis industry pioneer and TRUFF advisory board chairman, Bruce Linton who shared his perspective on TRUFF’s growth opportunities. Also joining the livestream was TRUFF CTO Sarah Hashkes who shared the company’s unique technology-driven marketing and branding strategy for psychedelics, which has been likened by some investors as the “Tesla of Psychedelics” Watch (OTC: TRUFF) Next Super Stock livestream Video: https://bit.ly/3u4aGR4 April 21 - TRUFF announces increase of Points of Sale for it’s iMicrodose Packs in the Netherlands by More Than 140% - $31 million cash on hand to fund growth. TRUFF CEO Todd Shapiro commented: "Over the last few months, we have continued executing on our goal to increase both the availability of our products and our brand's visibility. iMicrodose Packs powered by Red Light Holland are now available in 144% more locations than previously announced. Relationships held by our wholly owned distribution company SR Wholesale, already, account for 13 new locations, demonstrating some of the synergies that we strategically planned to realize from the recently closed acquisition. With over $31 million of cash and cash equivalents remaining on our balance sheet, we look forward to continuing to conservatively deploy capital into growth opportunities that support our long-term business objectives March 19 - TRUFF closes acquisition of SR Wholesale B.V., one of the Netherlands' premiere distributors for quality psychedelic truffles. In 2020, SR Wholesale generated over C$2.44 Million in revenues, and over $822,0001 in gross profit, with approximately $400,0001 of cash and working capital currently on hand. SR Wholesale has established a distribution network of over 400 companies that sell their products across Europe, including working with sub-distributors which provide products to over 1,000 shops in countries like the Netherlands, Germany, Spain, Czech, Greece, UK, France, and Portugal. Watch (OTC: TRUFF) Next Super Stock Video: https://bit.ly/3u4aGR4 ESE Entertainment (TSX.V: ESE) (OTC: ENTEF) CEO Konrad Wasiela: ”E-Sports M&A Pipeline With Over $100 million Annual Revenues”ESE Entertainment (TSX.V: ESE) (OTC: ENTEF) CEO Konrad Wasiela, a featured presenter at Wall Street Reporter’s NEXT SUPER STOCK investors livestream conference, recently updated investors on his goal of building ESE into a billions dollar global enterprise. Wasiela shared that “ESE now has a growing M&A pipeline with over $100 million annual revenues” and expected to close a significant number of these potential transactions in the coming months. ESE’s stated goal is to build a global E-Sports business with a valuation of $1 Billion+. Watch ESE (OTC: ENTEF) Next Super Stock livestream video: https://bit.ly/3qq59mb In his interview with Wall Street Reporter, ESE CEO Konrad Wasiela, says the company is now ready to scale - expanding it’s global footprint, with new partnerships with global brands like Porsche, driving revenue growth with aggressive focus on top line sales and margin expansion, and M&A opportunities. ESE is now rapidly expanding, with multiple revenue streams including, E-Sports infrastructure software powering global tournaments, exclusive digital media distribution, broadcast rights, and owning world-class leagues and teams, including it’s K1CK global E-Sports franchise. April 26 - ENTEF announces Rick Brace is joining its Board of Directors. Mr. Brace most recently served as the President of Rogers Media, the Sports and Media subsidiary of publicly-traded Rogers Communications (RCI). As President of Rogers Media, Rick Brace was responsible for driving strategy and overseeing operations for the company’s robust portfolio of media assets, which includes 42 TV stations, 51 radio stations, 56 publications, digital media, subscription-based content services, the Toronto Blue Jays, and Rogers Centre. Rick Brace commented: “During my time at Rogers it became abundantly clear that traditional media was feeling increasingly stronger headwinds brought on by the rollout and adoption of digital platforms that deliver content in new and innovative ways. Nowhere is this more prevalent than with the growth of esports which is seeing monumental year-over-year growth. ESE (OTC: ENTEF) has positioned itself at the forefront of this movement with a 360 approach, including rights ownership, team ownership, event production and distribution and I am both honoured and excited to join its board and be part of this revolution in our industry”. April 14 - ENTEF closes acquisition of Esports and gaming infrastructure company, WPG. In 2020, WPG’s assets generated revenue in excess of C$14,000,000. This transaction is anticipated to make ENTEF one of the largest esports infrastructure companies in the world, bridging esports companies with their fans and customers. Watch ESE (OTC: ENTEF) Next Super Stock livestream video: https://bit.ly/3qq59mb Skylight Health Group (TSX.V: SHG) (OTC: SHGFF) CEO, Prad Sekar: “Now At Inflection Point - Positioned for 10X Upside Revenue Growth Potential” Skylight Health Group (TSX.V: SHG) (OTC: SHGFF) was recently a featured presenter at Wall Street Reporter’s NEXT SUPER STOCK livestream investor conference. CEO Prad Sekar, outlined his vision for building Skylight into a multi-billion dollar business focused on the highly fragmented US healthcare market. Skylight already operates 30 clinics, in 14 states, with virtual telehealth overlay, serving over 120,000 patients - and is one of the fastest growing multi-disciplinary health systems in the United States. Watch Skylight (OTC: SHGFF) Next Super Stock video: http://bit.ly/3qAZAAr Skyllight is now at an inflection point. SHGFF revenues are expected to be $56 million and $5.5 million EBITDA run rates, with a recently announced acquisition. SHGFF boasts a profitable base of operations, no long-term debt and cash balance of $10 million. In his presentation, Skylight CEO Prad Sekar, explains how the company can increase revenues organically by about 10X, as it optimizes clinics for profitability by expansion of services to the existing patient base, with it’s proven business model, stating: "$200 Million Revenues Run Rate in 2021 Is Goal". Watch Skylight (OTC: SHGFF) Next Super Stock video: http://bit.ly/3qAZAAr WALL STREET REPORTER Wall Street Reporter (Est. 1843) is the leading financial news provider, focused on giving investors direct access to CEO's of promising, publicly-traded companies, and market experts. www.WallStreetReporter.com. Nothing in this news summary shall be construed as investment advice. Quotes/content may be edited for brevity and context.Full disclaimer, and relevant SEC 17B disclosures here: http://bit.ly/39kkE7K About Wall Street Reporter’s Next Super Stock conference: Wall Street Reporter's NEXT SUPER STOCK Live! conference is dedicated to featuring select companies that have near-term catalysts in place which can drive transformational growth (and stock appreciation) in the months ahead. Click here to join next livestream event: https://www.wallstreetreporter.com/next-superstock-online-investor-conference/ CONTACT: WALL STREET REPORTER (212) 871-2057 ext 7 www.WallStreetReporter.com
TORONTO, April 22, 2021 (GLOBE NEWSWIRE) -- Skylight Health Group Inc (TSXV:SHG; OTCQX: SHGFF) (“Skylight Health” or the “Company”), a multi-state primary care management group in the United States, announced today it has filed a preliminary short form base shelf prospectus (with the securities regulators in the following provinces of Canada; Alberta, British Columbia, Manitoba and Ontario) (the “Prospectus”) and a corresponding shelf registration statement on Form F-10 with the U.S. Securities and Exchange Commission. The Prospectus, when final and effective, will enable the Company to offer, issue and sell, from time to time: subordinate voting shares; restricted voting shares; limited voting shares; warrants; subscription receipts; debt securities; convertible securities; units; or any combination of such securities (collectively, the “Securities”) for up to an aggregate offering price of CA$100,000,000 (or its equivalent), in one or more transactions during the effective period of the Prospectus. Skylight Health has filed the Prospectus and corresponding registration statement in order to provide the Company with greater financial flexibility going forward. The registration statement is not yet effective, and the securities may not be sold, nor may offers to buy, be accepted prior to the time the registration statement becomes effective. “Our strategy continues to be organic growth and growth through acquisition, and we have built a robust pipeline of immediately accretive and strategic targets,” says Prad Sekar, Co-Founder and CEO. “As we move closer to our expected NASDAQ uplisting, it is more important than ever to have the financial flexibility to continue to execute on our growth and expansion strategy.” This news release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale, of the securities in any province, state, or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration of such securities under the securities laws of any such jurisdiction. A copy of the final short form base shelf prospectus can be found on SEDAR at www.sedar.com and a copy of the registration statement can be found on EDGAR at www.sec.gov. About Skylight Health Group Skylight Health Group (TSXV:SHG; OTCQX:SHGFF) is a healthcare services and technology company, working to positively impact patient health outcomes. The Company operates a US multi-state health network that comprises of physical multi-disciplinary medical clinics providing a range of services from primary care, sub-specialty, allied health and laboratory/diagnostic testing. The Company owns and operates a proprietary electronic health record system that supports the delivery of care to patients via telemedicine and other remote monitoring system integrations. The Company has operations serving 16 states and continues to expand in services and locations both organically and by way of strategic acquisitions. The Company primarily operates a traditional insurable fee-for-service model contracting with Medicare, Medicaid and other Commercial Payors. The Company also offers a disruptive subscription-based telemedicine service for the un/under-insured population who have limited access to urgent care due to cost. For more information, please visit www.skylighthealthgroup.com or contact: Investor Relations:Jackie Kellyinvestors@skylighthealthgroup.com416-301-2949 Currency Usage, Cautionary and Forward-Looking Statements All currency contained in this Press Release represent Canadian Dollars unless otherwise stated. Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Skylight Health's filings with Canadian securities regulators. When used in this news release, words such as "will, could, plan, estimate, expect, intend, may, potential, believe, should," and similar expressions, are forward-looking statements. Forward-looking statements may include, without limitation, statements regarding the Company's Prospectus and registration statement going effective and the Company’s anticipated uplist to NASDAQ. Although Skylight Health has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: the ability of Skylight Health to execute on its business strategy, continued revenue growth in accordance with management’s expectations, operating expenses continuing in accordance with management expectations, dependence on obtaining regulatory approvals; Skylight Health being able to find, complete and effectively integrate target acquisitions; change in laws relating to health care regulation; reliance on management; requirements for additional financing; competition; hindering market growth or other factors that may not currently be known by the Company. There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. Skylight Health disclaims any intention or obligation to update or revise such information, except as required by applicable law, and Skylight Health does not assume any liability for disclosure relating to any other company mentioned herein. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
NEW YORK, NY / ACCESSWIRE / April 20, 2021 / Skylight Health Group, Inc. (OTC:SHGFF) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on April 20, 2021 at 9:00 AM Eastern Time.